Epigral saw a 2% QoQ revenue increase to ₹603 Cr in Q3FY26, with Derivatives & Specialty contributing 52% of sales.

However, EBITDA margins tightened to 17% (vs 23% in Q2FY26) due to softer realizations and higher raw material costs.

For the first nine months of FY26, revenue dipped 7% to ₹1,807 Cr, impacted by extended monsoon and maintenance work.

Net profit for 9MFY26, excluding deferred tax benefit, stood at ₹171 Cr.

The company is strategically expanding its CPVC and Epichlorohydrin capacities, alongside a Wind Solar Hybrid Power Plant, all on schedule for H1FY27 commissioning to drive growth.

Management acknowledges temporary margin pressures but anticipates sustained positive market momentum and is finalizing new projects.

Key metrics for 9MFY26 include ROCE at 17% and Net Debt/EBITDA at 1.0x.